Browse > Article
http://dx.doi.org/10.17480/psk.2016.60.3.118

ABCB1 Polymorphisms and Imatinib Response in Chronic Myeloid Leukemia Patients: A Systematic Review and Meta-analysis  

Ha, Hye Min (College of Pharmacy, Inje University)
Chun, Pusoon (College of Pharmacy, Inje University)
Publication Information
YAKHAK HOEJI / v.60, no.3, 2016 , pp. 118-127 More about this Journal
Abstract
A growing number of studies have demonstrated that ABCB1 gene polymorphisms are associated with the variability of responses to imatinib. However, the effects of ABCB1 polymorphisms on imatinib response in chronic myeloid leukemia (CML) are inconsistent. The aim of the present study was to clarify the associations between ABCB1 polymorphisms and imatinib response in CML. A systematic literature review was performed. The databases of PubMed, Embase, and Cochrane Library were searched for all published studies from inception to December 2015. The following terms were used with functions of 'AND' and 'OR': 'chronic myeloid leukemia', 'CML', 'ABCB1', 'MDR1', 'polymorphism', 'SNP', and 'imatinib'. Using the Review Manager 5, odds ratios (ORs) were pooled to estimate the effect of ABCB1 polymorphisms on imatinib response in CML. The pooled analysis showed that ABCB1 2677 G allele was significantly associated with poor response to imatinib in African and Asian patients (GG vs TT, OR: 0.32, p<0.0001; GG+GT vs TT, OR: 0.44, p=0.0005). In subgroup analyses, African patients carrying ABCB1 1236 C allele exhibited higher risk for worse response, whereas Asian patients with 1236 C allele showed better response (CC+CT vs TT, OR: 0.41, p=0.008 for African; OR: 1.65, p=0.03 for Asian). There was no association between C3435T polymorphisms and imatinib response in African, Asian, and Caucasian CML patients.
Keywords
ABCB1 C1236T polymorphism; ABCB1 G2677T polymorphism; ABCB1 C3435T polymorphism; chronic myeloid leukemia; imatinib; response;
Citations & Related Records
연도 인용수 순위
  • Reference
1 Kurzrock, R., Kantarjian, H. M., Druker, B. J. and Talpaz, M. : Philadelphia chromosome-positive leukemias: from basic mechanisms to molecular therapeutics. Ann. Intern. Med. 138, 819 (2003).   DOI
2 Talpaz, M., Shah, N. P., Kantarjian, H., Donato, N., Nicoll, J., Paquette, R., Cortes, J., O'Brien, S., Nicaise, C., Bleickardt, E., Blackwood-Chirchir, M. A., Iyer, V., Chen, T. T., Huang, F., Decillis, A. P. and Sawyers, C. L. : Dasatinib in imatinibresistant Philadelphia chromosome-positive leukemias. N. Engl. J. Med. 354, 2531 (2006).   DOI
3 Baccarani, M., Deininger, M. W., Rosti, G., Hochhaus, A., Soverini, S., Apperley, J. F., Cervantes, F., Clark, R. E., Cortes, J. E., Guilhot, F., Hjorth-Hansen, H., Hughes, T. P., Kantarjian, H. M., Kim, D. W., Larson, R. A., Lipton, J. H., Mahon, F. X., Martinelli, G., Mayer, J., Muller, M. C., Niederwieser, D., Pane, F., Radich, J. P., Rousselot, P., Saglio, G., Saubele, S., Schiffer, C., Silver, R., Simonsson, B., Steegmann, J. L., Goldman, J. M. and Hehlmann, R. : European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013. Blood 122, 872 (2013).   DOI
4 Breccia, M., Alimena, G., Baccarani, M., Bocchia, M., Di Raimondo, F., Gambacorti-Passerini, C., Gozzini, A., Morra, E., Pane, F., Pregno, P., Rege-Cambrin, G., Rosti, G., Specchia, G., Vigneri, P. and Saglio, G. : Current management of CML patients: Summary of the Italian Consensus Meeting held in Rome, April 11-12, 2013. Crit. Rev. Oncol. Hematol. 90, 181 (2014).
5 National Institute for Health and Care Excellence. Guidance on the use of imatinib for chronic myeloid leukaemia. Available from URL: https://www.nice.org.uk/guidance/ta70/chapter/1-guidance. Accessed 25 January (2016).
6 Bixby, D. and Talpaz, M. : Mechanisms of resistance to tyrosine kinase inhibitors in chronic myeloid leukemia and recent therapeutic strategies to overcome resistance. Hematology Am. Soc. Hematol. Educ. Program 461 (2009).
7 Hodges, L. M., Markova, S. M., Chinn, L. W., Gow, J. M., Kroetz, D. L., Klein, T. E. and Altman, R. B. : Very important pharmacogene summary: ABCB1 (MDR1, P-glycoprotein). Pharmacogenet. Genomics 21, 152 (2011).   DOI
8 Zu, B., Li, Y., Wang, X., He, D., Huang, Z. and Feng, W. : MDR1 gene polymorphisms and imatinib response in chronic myeloid leukemia: a meta-analysis. Pharmacogenomics 15, 667 (2014).   DOI
9 Zheng, Q., Wu, H., Yu, Q., Kim, D. H., Lipton, J. H., Angelini, S., Soverini, S., Vivona, D., Takahashi, N. and Cao, J. : ABCB1 polymorphisms predict imatinib response in chronic myeloid leukemia patients: a systematic review and meta-analysis. Pharmacogenomics J. 15, 127 (2015).   DOI
10 Wang, J. L., Liu, H. J., Li, F., Yang, W. Y., Wang, J. M., Tan, S. F. and Wang, Q. : Multidrug resistance gene (MDR1) polymorphisms may not be directly associated with response to imatinib in chronic myeloid leukemia. Genet. Mol. Res. 14, 14967 (2015).   DOI
11 Wells, G. A., Shea, B., O'Connell, D., Peterson, J., Welch, V., Losos, M. and Tugwell, P. : The Newcastle-Ottawa scale (NOS) for assessing the quality of nonrandomised studies in meta-analysis. Ottawa Hospital Research Institute. Available from URL: http://www.ohri.ca/programs/clinical_epidemiology/oxford.asp. Accessed 20 January (2016).
12 Zheng, J. S., Hu, X. J., Zhao, Y. M., Yang, J. and Li, D. : Intake of fish and marine n-3 polyunsaturated fatty acids and risk of breast cancer: meta-analysis of data from 21 independent prospective cohort studies. BMJ 346, f3706 (2013).   DOI
13 Xuan, C., Zhang, B. B., Li, M., Deng, K. F., Yang, T. and Zhang, X. E. : No association between APOE ${\varepsilon}$ 4 allele and multiple sclerosis susceptibility: a meta-analysis from 5472 cases and 4727 controls. J. Neurol. Sci. 308, 110 (2011).   DOI
14 Maffioli, M., Camos, M., Gaya, A., Hernandez-Boluda, J. C., Alvarez-Larran, A., Domingo, A., Granell, M., Guillem, V., Vallansot, R., Costa, D., Bellosillo, B., Colomer, D. and Cervantes, F. : Correlation between genetic polymorphisms of the hOCT1 and MDR1 genes and the response to imatinib in patients newly diagnosed with chronic-phase chronic myeloid leukemia. Leuk. Res. 35, 1014 (2011).   DOI
15 Zhang, B. B., Xuan, C., Deng, K. F., Wu, N. and Lun, L. M. : Association between the MDR1 gene variant C3435T and risk of leukaemia: a meta-analysis. Eur. J. Cancer Care (Engl). 22, 617 (2013).   DOI
16 Ali, M. A. and Elsalakawy, W. A. : ABCB1 haplotypes but not individual SNPs predict for optimal response/failure in Egyptian patients with chronic-phase chronic myeloid leukemia receiving imatinib mesylate. Med. Oncol. 31, 279 (2014).   DOI
17 Elghannam, D. M., Ibrahim, L., Ebrahim, M. A., Azmy, E. and Hakem, H. : Association of MDR1 gene polymorphism (G2677T) with imatinib response in Egyptian chronic myeloid leukemia patients. Hematology 19, 123 (2014).   DOI
18 Vivona, D., Bueno, C. T., Lima, L. T., Hirata, R. D., Hirata, M. H., Luchessi, A. D., Zanichelli, M. A., Chiattone, C. S. and Guerra-Shinohara, E. M. : ABCB1 haplotype is associated with major molecular response in chronic myeloid leukemia patients treated with standard-dose of imatinib. Blood Cells Mol. Dis. 48, 132 (2012).   DOI
19 Gromicho, M., Magalhaes, M., Torres, F., Dinis, J., Fernandes, A. R., Rendeiro, P., Tavares, P., Laires, A., Rueff, J. and Sebastiao Rodrigues, A. : Instability of mRNA expression signatures of drug transporters in chronic myeloid leukemia patients resistant to imatinib. Oncol. Rep. 29, 741 (2013).   DOI
20 Seong, S. J., Lim, M., Sohn, S. K., Moon, J. H., Oh, S. J., Kim, B. S., Ryoo, H. M., Chung, J. S., Joo, Y. D., Bang, S. M., Jung, C. W., Kim, D. H., Park, S. Y., Yoon, S. S., Kim, I., Lee, H. G., Won, J. H., Min, Y. H., Cheong, J. W., Park, J. S., Eom, K. S., Hyun, M. S., Kim, M. K., Kim, H., Park, M. R., Park, J., Kim, C. S., Kim, H. J., Kim, Y. K., Park, E. K., Zang, D. Y., Jo, D. Y., Lee, H. W. and Yoon, Y. R. : Influence of enzyme and transporter polymorphisms on trough imatinib concentration and clinical response in chronic myeloid leukemia patients. Ann. Oncol. 24, 756 (2013).   DOI
21 Au, A., Aziz Baba, A., Goh, A. S., Wahid Fadilah, S. A., The, A., Rosline, H. and Ankathil, R. : Association of genotypes and haplotypes of multi-drug transporter genes ABCB1 and ABCG2 with clinical response to imatinib mesylate in chronic myeloid leukemia patients. Biomed. Pharmacother. 68, 343 (2014).   DOI
22 Salimizand, H., Amini, S., Abdi, M., Ghaderi, B. and Azadi, N. A. : Concurrent effects of ABCB1 C3435T, ABCG2 C421A, and XRCC1 Arg194Trp genetic polymorphisms with risk of cancer, clinical output, and response to treatment with imatinib mesylate in patients with chronic myeloid leukemia. Tumour. Biol. DOI 10.1007/s13277-015-3874-4 (2015).   DOI
23 Takahashi, N., Miura, M., Scott, S. A., Kagaya, H., Kameoka, Y., Tagawa, H., Saitoh, H., Fujishima, N., Yoshioka, T., Hirokawa, M. and Sawada, K. : Influence of CYP3A5 and drug transporter polymorphisms on imatinib trough concentration and clinical response among patients with chronic phase chronic myeloid leukemia. J. Hum. Genet. 55, 731 (2010).   DOI
24 Ni, L. N., Li, J. Y., Miao, K. R., Qiao, C., Zhang, S. J., Qiu, H. R. and Qian, S. X. : Multidrug resistance gene (MDR1) polymorphisms correlate with imatinib response in chronic myeloid leukemia. Med. Oncol. 28, 265 (2011).   DOI
25 Dulucq, S., Bouchet, S., Turcq, B., Lippert, E., Etienne, G., Reiffers, J., Molimard, M., Krajinovic, M. and Mahon, F. X. : Multidrug resistance gene (MDR1) polymorphisms are associated with major molecular responses to standard-dose imatinib in chronic myeloid leukemia. Blood 112, 2024 (2008).   DOI
26 Anthony, A., Ankathil, R., Ai-Sim, G., Fadilah, S. A. W. and Baba, A. A. : Influence of ABCB1 C3435T and ABCG2 C421A gene polymorphisms in response to imatinib mesylate in chronic myeloid leukemia patients. IJESD 3, 274 (2012).
27 Shinohara, Y., Takahashi, N., Nishiwaki, K., Hino, M., Kashimura, M., Wakita, H., Hatano, Y., Hirasawa, A., Nakagawa, Y., Itoh, K., Masuoka, H., Aotsuka, N., Matsuura, Y., Takahara, S., Sano, K., Kuroki, J., Hata, T., Nakamae, H., Mugitani, A., Nakane, T., Miyazaki, Y., Niioka, T., Miura, M. and Sawada, K. : A multicenter clinical study evaluating the confirmed complete molecular response rate in imatinib-treated patients with chronic phase chronic myeloid leukemia by using the international scale of real-time quantitative polymerase chain reaction. Haematologica. 98, 1407 (2013).   DOI
28 Kassogue, Y., Dehbi, H., Quachouh, M., Quessar, A., Benchekroun, S. and Nadifi, S. : Lack of association of multidrug resistance gene-1 polymorphisms with treatment outcome in chronic myeloid leukemia patients treated with imatinib. MEJC 6, 229 (2015).
29 Sailaja, K., Surekha, D., Rao, D. N., Raghunadharao, D. and Vishnupriya, S. : Association of MDR1 gene polymorphism (G2677T) with chronic myeloid leukemia. Biology and Medicine 2, 17 (2010).
30 Griffin, J. D., Guerin, A., Chen, L., Macalalad, A. R., Luo, J., Ionescu-Ittu, R. and Wu, E. Q. : Comparing nilotinib with dasatinib as second-line therapies in patients with chronic myelogenous leukemia resistant or intolerant to imatinib--a retrospective chart review analysis. Curr. Med. Res. Opin. 29, 623 (2013).   DOI
31 Dulucq, S., Preudhomme, C., Guilhot, F. and Mahon, F.-X. : Response: is there really a relationship between Multidrug Resistance Gene (MDR1) polymorphisms and major molecular response to imatinib in chronic myeloid leukemia? Blood 116, 6145 (2010).   DOI
32 Kim, D. H., Kong, J. H., Byeun, J. Y., Jung, C. W., Xu, W., Liu, X., Kamel-Reid, S., Kim, Y. K., Kim, H. J. and Lipton, J. H. : The IFNG (IFN-gamma) genotype predicts cytogenetic and molecular response to imatinib therapy in chronic myeloid leukemia. Clin. Cancer Res. 16, 5339 (2010).   DOI
33 Marin, D., Bazeos, A., Mahon, F. X., Eliasson, L., Milojkovic, D., Bua, M., Apperley, J. F., Szydlo, R., Desai, R., Kozlowski, K., Paliompeis, C., Latham, V., Foroni, L., Molimard, M., Reid, A., Rezvani, K., de Lavallade, H., Guallar, C., Goldman, J. and Khorashad, J. S. : Adherence is the critical factor for achieving molecular responses in patients with chronic myeloid leukemia who achieve complete cytogenetic responses on imatinib. J. Clin. Oncol. 28, 2381 (2010).   DOI
34 Deenik, W., van der Holt, B., Janssen, J. J., Chu, I. W., Valk, P. J., Ossenkoppele, G. J., van der Heiden, I. P., Sonneveld, P., van Schaik, R. H. and Cornelissen, J. J. : Polymorphisms in the multidrug resistance gene MDR1 (ABCB1) predict for molecular resistance in patients with newly diagnosed chronic myeloid leukemia receiving high-dose imatinib. Blood 116, 6144; author reply 6145 (2010).   DOI